ANKRD36 Is Involved in Hypertension by Altering ENaC Genes Expression

Yupeng Yan,Jin’e Wang,Liang Yu,Bing Cui,Hongrui Wang,Xiao Xiao,Yu Zhang,Jun Zheng,Jingjun Wang,Rutai Hui,Yibo Wang,Jin'e Wang
DOI: https://doi.org/10.1161/circresaha.121.319883
IF: 23.213
2021-10-07
Circulation Research
Abstract:Rationale: Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases. Getting deep insight into the pathogenesis of hypertension is necessary. Objective: To investigate the role of ANKRD36 in hypertension. Methods and Results: We firstly recruited an essential hypertension cohort, and then performed genome-wide transcriptome analysis with peripheral blood mRNA. ANKRD36 (ankyrin repeat domain 36) was found to be significantly lower expressed in hypertension. The anchorin repeat domain mediates a variety of protein-protein interactions. The ENaC genes expression was found up-regulated in HUVECs with ANKRD36 knockdown by using Affymetrix expression profile chip. In HKC and HEK293T cells, ANKRD36 overexpression significantly down-regulated ENaC genes expression, and ANKRD36 knockdown up-regulated their expression. The ChIP assay and YY1 knockdown showed the expression of ENaC was regulated by ANKRD36 via YY1, a dual function transcription factor ubiquitously expressed in human tissues. CO-IP and fluorescence resonance energy transfer assay confirmed the interaction between ANKRD36 and YY1. The nucleo-cytoplasmic ratio of YY1 decreased when ANKRD36 was overexpressed, and also increased when ANKRD36 was knocked down. ANK2 domain of ANKRD36 was critical to its interacting with YY1. Ankrd36 knockout mice showed higher blood pressure levels and Na+ reabsorption, especially when fed with high-salt diet. Higher ENaC genes expression was observed in renal tubular epithelial cells from the knockout mice, and Yy1 knockdown mitigated the alteration. Ankrd36 knockout mice also showed more sensitive response to ENaC inhibitor amiloride treatment. Conclusions: We identified that ANKRD36 was involved in blood pressure regulation by interacting with YY1 and then altering ENaC genes expression. Lower expressed ANKRD36 in hypertension might be a potential therapeutic target, and the application of ENaC inhibitors on hypertension treatment might be extended when serum K+ levels are closely monitored.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
What problem does this paper attempt to address?